Agenda

The goal of this symposium is to bring together leading scientific and clinical investigators of acute leukemias in children and adolescents with trisomy 21, to survey the current state of the field, and foster collaborations to address knowledge gaps and improve outcomes.

Please note that the time is Eastern Standard Time.

Tuesday, May 10, 2022

10:00 am - 10:30 am EST
Welcome

Goals and Vision
Anupam Verma & Karen Rabin


Introduction to the INCLUDE Project
Melissa Parisi


The patient and parent experience with acute leukemia and Down syndrome
Amy and Kent Bratsch

Session 1: Transient abnormal myelopoiesis (TAM) and myeloid leukemia associated with Down syndrome (ML-DS)
Chair:  Hans Hitzler

10:30 am - 11:00 am EST
Disease Mechanisms

Somatic and germline mutations in pediatric AML and impact on treatment
Soheil Meshinchi


Predisposition, pre-leukemia and progression – the unique disease mechanism of myeloid leukemia in children with Down syndrome
Sebastien Malinge

11:00 am - 11:15 am EST
Transient abnormal myelopoiesis of DS

Hans Hitzler

11:15 am - 11:45 am EST
Clinical management of ML-DS

Survival outcomes, risk groups and toxicity – the experience of the BFM Study group
Jan-Henning Klusmann


From ceiling to floor—risk stratification of treatment intensity for ML-DS - the Children’s Oncology Group experience
Jason Berman

11:45 am - 12:05 pm EST
Panel Discussion

Panelists:  

Hans Hitzler
Soheil Meshinchi
Sebastien Malinge
Jan-Henning Klusmann
Jason Berman
John Crispino

12:05 pm - 12:30 pm EST
Lunch Break

Session 2: Acute lymphoblastic leukemia (ALL) and Down syndrome
Chair: Karen Rabin

12:30 pm - 01:15 pm EST
Biology

Disease mechanisms of ALL in children with DS
Shai Izraeli


Germline genetic susceptibility to ALL in children with DS
Philip Lupo


Somatic landscape of DS-associated ALL
Jun Yang

01:15 pm - 01:30 pm EST
Treatment approaches and toxicity management in newly diagnosed DS-ALL

Karen Rabin

01:30 pm - 01:50 pm EST
Panel Discussion

Panelists:

Karen Rabin
Shai Izraeli
Philip Lupo
Jun Yang
Adam de Smith

Session 3: Relapsed leukemias and late effects in Down syndrome
Chair: Nirali Shah

01:50 pm - 02:20 pm EST
Relapsed DS ALL

Treatment strategies for relapsed DS ALL
Amanda Li


CAR T-cell therapy in DS ALL
Shannon Maude

02:20 pm - 02:35 pm EST
From favorable prognosis of primary ML-DS to challenges at relapse

Alan Gamis

02:35 pm - 02:50 pm EST
Hematopoietic stem cell transplantation for children with Down syndrome

Christina Peters

02:50 pm - 03:05 pm EST
Potential late effects of acute leukemia treatment in children with DS

M. Monica Gramatges

03:05 pm - 03:25 pm EST
Panel Discussion

Panelists:

Nirali Shah
Amanda Li
Shannon Maude
Alan Gamis
Christina Peters
M. Monica Gramatges
Sarah Tasian
John Levine

03:25 pm - 03:40 pm EST
Break

Session 4: Optimizing clinical trial and data infrastructure
Chair: Anupam Verma

03:40 pm - 03:55 pm EST
Inclusion of patients with DS in clinical trials

Donna Snyder

03:55 pm - 04:10 pm EST
Consent/assent for patients with DS

Christine Grady

04:10 pm - 04:25 pm EST
Inclusion of patients with Down Syndrome in clinical trials and implications on trial design

Anupam Verma

04:25 pm - 04:40 pm EST
NCI projects and DS related efforts

Malcolm Smith

04:40 pm - 04:55 pm EST
INCLUDE-Data Resource Center

Joaquin Espinosa

04:55 pm - 05:15 pm EST
Panel Discussion

Panelists:

Anupam Verma
Donna Snyder
Christine Grady
Malcolm Smith
Joaquin Espinosa
Maureen O’Brien

05:15 pm - 05:30 pm EST
Concluding remarks

Karen Rabin
Anupam Verma
Amy and Kent Bratsch